Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.

Shi L, Wu TT, Wang Z, Xue JY, Xu YG.

Bioorg Med Chem. 2014 Sep 1;22(17):4735-44. doi: 10.1016/j.bmc.2014.07.008. Erratum in: Bioorg Med Chem. 2015 Aug 1;23(15):5075.

PMID:
25082515
2.

Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.

Shi L, Wu TT, Wang Z, Xue JY, Xu YG.

Eur J Med Chem. 2014 Sep 12;84:698-707. doi: 10.1016/j.ejmech.2014.07.071.

PMID:
25064347
3.

Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.

Lu L, Zhao TT, Liu TB, Sun WX, Xu C, Li DD, Zhu HL.

Chem Pharm Bull (Tokyo). 2016 Nov 1;64(11):1570-1575.

4.

Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.

Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y.

Bioorg Med Chem. 2011 Aug 1;19(15):4529-35. doi: 10.1016/j.bmc.2011.06.022.

PMID:
21724404
5.

Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.

Peng FW, Wu TT, Ren ZW, Xue JY, Shi L.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5137-41. doi: 10.1016/j.bmcl.2015.10.006.

PMID:
26475519
6.

Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.

Ravez S, Barczyk A, Six P, Cagnon A, Garofalo A, Goossens L, Depreux P.

Eur J Med Chem. 2014 May 22;79:369-81. doi: 10.1016/j.ejmech.2014.04.007.

PMID:
24747748
7.

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.

Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L.

Eur J Med Chem. 2016 Jan 27;108:495-504. doi: 10.1016/j.ejmech.2015.12.016. Review.

PMID:
26717201
8.

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.

Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ.

Eur J Med Chem. 2014 Jan;71:1-14. doi: 10.1016/j.ejmech.2013.10.058.

PMID:
24269511
9.

Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.

Peng FW, Xuan J, Wu TT, Xue JY, Ren ZW, Liu DK, Wang XQ, Chen XH, Zhang JW, Xu YG, Shi L.

Eur J Med Chem. 2016 Feb 15;109:1-12. doi: 10.1016/j.ejmech.2015.12.033.

PMID:
26741358
10.

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.

Zhang HQ, Gong FH, Li CG, Zhang C, Wang YJ, Xu YG, Sun LP.

Eur J Med Chem. 2016 Feb 15;109:371-9. doi: 10.1016/j.ejmech.2015.12.032.

PMID:
26826581
11.

Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.

Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.

Eur J Med Chem. 2013 Sep;67:373-83. doi: 10.1016/j.ejmech.2013.06.057.

PMID:
23900004
12.

Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.

Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S.

Bioorg Med Chem. 2013 Dec 15;21(24):7686-98. doi: 10.1016/j.bmc.2013.10.028.

PMID:
24216091
13.

Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.

Yassen AS, Elshihawy HE, Said MM, Abouzid KA.

Chem Pharm Bull (Tokyo). 2014;62(5):454-66.

14.

Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.

Eldehna WM, Fares M, Ibrahim HS, Aly MH, Zada S, Ali MM, Abou-Seri SM, Abdel-Aziz HA, Abou El Ella DA.

Eur J Med Chem. 2015 Jul 15;100:89-97. doi: 10.1016/j.ejmech.2015.05.040.

PMID:
26071861
15.

Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.

Shan Y, Gao H, Shao X, Wang J, Pan X, Zhang J.

Eur J Med Chem. 2015 Oct 20;103:80-90. doi: 10.1016/j.ejmech.2015.08.045.

PMID:
26342134
16.

Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.

Abbas HA, Al-Marhabi AR, Eissa SI, Ammar YA.

Bioorg Med Chem. 2015 Oct 15;23(20):6560-72. doi: 10.1016/j.bmc.2015.09.023.

PMID:
26420384
17.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Zhang D, Ai J, Liang Z, Li C, Peng X, Ji Y, Jiang H, Geng M, Luo C, Liu H.

Bioorg Med Chem. 2012 Sep 1;20(17):5169-80. doi: 10.1016/j.bmc.2012.07.007.

PMID:
22863529
18.

Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.

Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, Gong P.

Bioorg Med Chem. 2013 Jun 1;21(11):2843-55. doi: 10.1016/j.bmc.2013.04.013.

PMID:
23628470
19.

Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime.

Gao H, Su P, Shi Y, Shen X, Zhang Y, Dong J, Zhang J.

Eur J Med Chem. 2015 Jan 27;90:232-40. doi: 10.1016/j.ejmech.2014.11.032.

PMID:
25461323
20.

Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.

Zhu W, Wang W, Xu S, Wang J, Tang Q, Wu C, Zhao Y, Zheng P.

Bioorg Med Chem. 2016 Apr 15;24(8):1749-56. doi: 10.1016/j.bmc.2016.02.046.

PMID:
26964675
Items per page

Supplemental Content

Support Center